<ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
<p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免费报告) - Cantor Fitzgerald 的股票研究分析师在 11 月 11 日星期二向客户和投资者发布的研究报告中上调了对 CRISPR Therapeutics 2026 财年的收益预期。Cantor Fitzgerald 分析师 E. Schmidt 现在预计该公司将发布每股收益（$6.22），高于之前预测的（$6.71）。CRISPR Therapeutics 当前全年的共识收益预期为每股（$5.16）。</p>
<p>其他几位股票分析师最近也对 CRSP 发布了报告。Needham &amp; Company LLC 将 CRISPR Therapeutics 的目标价格从$81.00 下调至$80.00，并在周一的研究报告中给予该公司 “买入” 评级。Wells Fargo &amp; Company 在 10 月 13 日的研究报告中对 CRISPR Therapeutics 设定了$75.00 的目标价格。HC Wainwright 在 9 月 23 日的研究报告中重申了 “买入” 评级，并对 CRISPR Therapeutics 设定了$80.00 的目标价格。Robert W. Baird 在周二的报告中将 CRISPR Therapeutics 的目标价格从$52.00 下调至$44.00，并对该股票给予 “中性” 评级。最后，Zacks Research 在 8 月 26 日的研究报告中将 CRISPR Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。共有 11 位股票研究分析师对该股票给予 “买入” 评级，8 位给予 “持有” 评级，2 位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的当前共识评级为 “持有”，平均目标价格为$67.84。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p><strong>获取我们最新的 CRSP 股票分析</strong></p>
<h2>CRISPR Therapeutics 股价下跌 3.1%</h2>
<p>CRSP 股票在周四的交易时段下跌$1.60，达到$50.59。该公司 745,808 股股票被交易，较其平均交易量 2,550,948 有所减少。CRISPR Therapeutics 的 1 年最低价为$30.04，1 年最高价为$78.48。该股票的 50 日移动平均价格为$63.02，200 日移动平均价格为$53.44。该股票的市值为$48.2 亿，市盈率为-9.09，贝塔值为 1.89。</p>
<ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
<p>CRISPR Therapeutics (NASDAQ:CRSP - 获取免费报告) 最近在 11 月 10 日星期一发布了季度收益数据。该公司报告的每股收益为（$1.17），超过分析师的共识预期（$1.32）$0.15。CRISPR Therapeutics 的净利润率为-1,273.70%，股本回报率为-21.23%。该公司本季度的收入为$0.89 百万，而分析师预期为$8.74 百万。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。SVB Wealth LLC 在第一季度购买了 CRISPR Therapeutics 的新股份，价值约$25,000。Costello Asset Management INC 在第一季度购买了 CRISPR Therapeutics 的新股份，价值约$27,000。Atlantic Union Bankshares Corp 在第二季度购买了 CRISPR Therapeutics 的新股份，价值$33,000。Thompson Investment Management Inc.在第三季度购买了 CRISPR Therapeutics 的新股份，价值约$33,000。最后，Optiver Holding B.V.在第三季度将其在 CRISPR Therapeutics 的股份增加了 71.4%。Optiver Holding B.V.现在拥有该公司 504 股股票，价值$33,000，此前在上个季度又购买了 210 股。对冲基金和其他机构投资者持有该公司 69.20% 的股份。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席法律顾问 James R. Kasinger 在 10 月 14 日星期二出售了 1,076 股公司的股票。股票以平均价格$66.60 出售，总价值为$71,661.60。出售完成后，首席法律顾问直接持有该公司 83,402 股股票，价值约$5,554,573.20。这笔交易代表其持股减少了 1.27%。该交易在向 SEC 提交的文件中披露，SEC 网站上可以访问。此外，首席执行官 Samarth Kulkarni 在 10 月 17 日星期五出售了 50,895 股公司的股票。股票以平均价格$67.91 出售，总交易额为$3,456,279.45。交易完成后，首席执行官直接持有该公司 254,201 股股票，价值约$17,262,789.91。这代表其持股减少了 16.68%。该交易的披露可在 SEC 文件中找到。在上个季度，内部人士出售了 56,213 股公司股票，价值$3,810,458。公司内部人士持有该公司 4.30% 的股份。</p>
<h2>关于 CRISPR Therapeutics</h2>
<p>（获取免费报告）</p>
<p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发针对严重疾病的变革性基因治疗药物。CRISPR/Cas9 是一项革命性的基因编辑技术，允许对基因组 DNA 进行精确、定向的更改。CRISPR Therapeutics 在包括血红蛋白病、肿瘤学、再生医学和罕见疾病等广泛疾病领域建立了一系列治疗项目。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比 CRISPR Therapeutics 更好</li>
<li>10 只最佳航空公司股票</li>
<li>AMD 到$300 看起来很容易——这是为什么$500 可能是下一个</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>超过$50 亿的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>公用事业股票解析——如何以及为什么投资公用事业</li>
<li>4 只高收益房地产股票，适合投资者采取防御性策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 CRISPR Therapeutics 吗？</h2>
<p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRISPR治疗

<p>Cantor Fitzgerald 分析师已上调 CRISPR Therapeutics 2026 财年的盈利预期，预测每股损失将小于之前预期。该股票的共识评级为 “持有”，平均目标价为 67.84 美元。最近的交易中，股价下跌了 3.1%，至 50.59 美元。机构投资者活跃，报告了显著的内部交易。尽管公司的最近季度盈利超出预期，但净利润率和股本回报率均为负值</p>

<ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
</div><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($6.22) for the year, up from their prior forecast of ($6.71). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免费报告) - Cantor Fitzgerald 的股票研究分析师在 11 月 11 日星期二向客户和投资者发布的研究报告中上调了对 CRISPR Therapeutics 2026 财年的收益预期。Cantor Fitzgerald 分析师 E. Schmidt 现在预计该公司将发布每股收益（$6.22），高于之前预测的（$6.71）。CRISPR Therapeutics 当前全年的共识收益预期为每股（$5.16）。</p>
</div><p>Several other equities analysts have also recently issued reports on CRSP. Needham &amp; Company LLC decreased their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a &#34;buy&#34; rating for the company in a research note on Monday. Wells Fargo &amp; Company set a $75.00 price target on shares of CRISPR Therapeutics in a research report on Monday, October 13th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Robert W. Baird dropped their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 26th. Eleven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $67.84.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对 CRSP 发布了报告。Needham &amp; Company LLC 将 CRISPR Therapeutics 的目标价格从$81.00 下调至$80.00，并在周一的研究报告中给予该公司 “买入” 评级。Wells Fargo &amp; Company 在 10 月 13 日的研究报告中对 CRISPR Therapeutics 设定了$75.00 的目标价格。HC Wainwright 在 9 月 23 日的研究报告中重申了 “买入” 评级，并对 CRISPR Therapeutics 设定了$80.00 的目标价格。Robert W. Baird 在周二的报告中将 CRISPR Therapeutics 的目标价格从$52.00 下调至$44.00，并对该股票给予 “中性” 评级。最后，Zacks Research 在 8 月 26 日的研究报告中将 CRISPR Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。共有 11 位股票研究分析师对该股票给予 “买入” 评级，8 位给予 “持有” 评级，2 位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的当前共识评级为 “持有”，平均目标价格为$67.84。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on CRSP</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 CRSP 股票分析</strong></p>
</div><h2>CRISPR Therapeutics Trading Down 3.1%</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 股价下跌 3.1%</h2>
</div><p>Shares of CRSP stock traded down $1.60 during trading hours on Thursday, reaching $50.59. 745,808 shares of the company's stock were exchanged, compared to its average volume of 2,550,948. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The stock's fifty day moving average price is $63.02 and its two-hundred day moving average price is $53.44. The stock has a market cap of $4.82 billion, a PE ratio of -9.09 and a beta of 1.89.</p>
<div class="lb-trans"><p>CRSP 股票在周四的交易时段下跌$1.60，达到$50.59。该公司 745,808 股股票被交易，较其平均交易量 2,550,948 有所减少。CRISPR Therapeutics 的 1 年最低价为$30.04，1 年最高价为$78.48。该股票的 50 日移动平均价格为$63.02，200 日移动平均价格为$53.44。该股票的市值为$48.2 亿，市盈率为-9.09，贝塔值为 1.89。</p>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million.</p>
<div class="lb-trans"><p>CRISPR Therapeutics (NASDAQ:CRSP - 获取免费报告) 最近在 11 月 10 日星期一发布了季度收益数据。该公司报告的每股收益为（$1.17），超过分析师的共识预期（$1.32）$0.15。CRISPR Therapeutics 的净利润率为-1,273.70%，股本回报率为-21.23%。该公司本季度的收入为$0.89 百万，而分析师预期为$8.74 百万。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at about $25,000. Costello Asset Management INC bought a new stake in CRISPR Therapeutics during the first quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new position in CRISPR Therapeutics in the second quarter valued at $33,000. Thompson Investment Management Inc. purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $33,000. Finally, Optiver Holding B.V. boosted its stake in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。SVB Wealth LLC 在第一季度购买了 CRISPR Therapeutics 的新股份，价值约$25,000。Costello Asset Management INC 在第一季度购买了 CRISPR Therapeutics 的新股份，价值约$27,000。Atlantic Union Bankshares Corp 在第二季度购买了 CRISPR Therapeutics 的新股份，价值$33,000。Thompson Investment Management Inc.在第三季度购买了 CRISPR Therapeutics 的新股份，价值约$33,000。最后，Optiver Holding B.V.在第三季度将其在 CRISPR Therapeutics 的股份增加了 71.4%。Optiver Holding B.V.现在拥有该公司 504 股股票，价值$33,000，此前在上个季度又购买了 210 股。对冲基金和其他机构投资者持有该公司 69.20% 的股份。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 56,213 shares of company stock valued at $3,810,458. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席法律顾问 James R. Kasinger 在 10 月 14 日星期二出售了 1,076 股公司的股票。股票以平均价格$66.60 出售，总价值为$71,661.60。出售完成后，首席法律顾问直接持有该公司 83,402 股股票，价值约$5,554,573.20。这笔交易代表其持股减少了 1.27%。该交易在向 SEC 提交的文件中披露，SEC 网站上可以访问。此外，首席执行官 Samarth Kulkarni 在 10 月 17 日星期五出售了 50,895 股公司的股票。股票以平均价格$67.91 出售，总交易额为$3,456,279.45。交易完成后，首席执行官直接持有该公司 254,201 股股票，价值约$17,262,789.91。这代表其持股减少了 16.68%。该交易的披露可在 SEC 文件中找到。在上个季度，内部人士出售了 56,213 股公司股票，价值$3,810,458。公司内部人士持有该公司 4.30% 的股份。</p>
</div><h2>About CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>关于 CRISPR Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发针对严重疾病的变革性基因治疗药物。CRISPR/Cas9 是一项革命性的基因编辑技术，允许对基因组 DNA 进行精确、定向的更改。CRISPR Therapeutics 在包括血红蛋白病、肿瘤学、再生医学和罕见疾病等广泛疾病领域建立了一系列治疗项目。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>10 Best Airline Stocks to Buy</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 CRISPR Therapeutics 更好</li>
<li>10 只最佳航空公司股票</li>
<li>AMD 到$300 看起来很容易——这是为什么$500 可能是下一个</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>超过$50 亿的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>公用事业股票解析——如何以及为什么投资公用事业</li>
<li>4 只高收益房地产股票，适合投资者采取防御性策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

股票分析师发布了对 CRSP 2026 财年收益的预测